Piramal Pharma Commits $90M to US Expansion; Turbhe Site Gets USFDA Nod

🏭

will invest $90 million to expand its Lexington and Riverview facilities in the US, catering to rising demand and onshoring trends. Lexington will complete expansion by late 2027, Riverview by end-2025. Meanwhile, its Turbhe site received an Establishment Inspection Report (EIR) with VAI status from the USFDA.